| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
|
Jhaveri, K.L.
|
|
|
30 |
11 |
p. 1821-1830
|
article
|
| 2 |
Advances in targeted alpha therapy for prostate cancer
|
De Vincentis, G.
|
|
|
30 |
11 |
p. 1728-1739
|
article
|
| 3 |
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
|
Guo, Y.
|
|
|
30 |
11 |
p. 1831-1839
|
article
|
| 4 |
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
|
Small, E.J.
|
|
|
30 |
11 |
p. 1813-1820
|
article
|
| 5 |
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
|
Kulke, M.H.
|
|
|
30 |
11 |
p. 1846
|
article
|
| 6 |
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
|
Bartlett, J.M.S.
|
|
|
30 |
11 |
p. 1776-1783
|
article
|
| 7 |
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
|
Batth, I.S.
|
|
|
30 |
11 |
p. 1845
|
article
|
| 8 |
Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors
|
Shen, C.
|
|
|
30 |
11 |
p. 1847
|
article
|
| 9 |
Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess
|
Ciccolini, J.
|
|
|
30 |
11 |
p. 1690-1691
|
article
|
| 10 |
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
|
Stintzing, S.
|
|
|
30 |
11 |
p. 1796-1803
|
article
|
| 11 |
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
|
Long, G.V.
|
|
|
30 |
11 |
p. 1848
|
article
|
| 12 |
Defining sarcoma specialist center: revisiting the volume effect
|
Moris, Dimitrios
|
|
|
30 |
11 |
p. 1840
|
article
|
| 13 |
Development of adaptive immune effector therapies in solid tumors
|
Comoli, P.
|
|
|
30 |
11 |
p. 1740-1750
|
article
|
| 14 |
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
|
Ferreira, A.R.
|
|
|
30 |
11 |
p. 1784-1795
|
article
|
| 15 |
Early evolutionary divergence between papillary and anaplastic thyroid cancers
|
Capdevila, J.
|
|
|
30 |
11 |
p. 1843
|
article
|
| 16 |
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees †
|
Horwich, A.
|
|
|
30 |
11 |
p. 1697-1727
|
article
|
| 17 |
Editorial Board
|
|
|
|
30 |
11 |
p. i-ii
|
article
|
| 18 |
Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety
|
Vignot, S.
|
|
|
30 |
11 |
p. 1694-1696
|
article
|
| 19 |
Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
|
Simmet, V.
|
|
|
30 |
11 |
p. 1751-1759
|
article
|
| 20 |
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
|
Bamias, A.
|
|
|
30 |
11 |
p. 1841
|
article
|
| 21 |
International consensus for advanced bladder cancer: an opportunity between the lines
|
Murthy, V.
|
|
|
30 |
11 |
p. 1688-1690
|
article
|
| 22 |
Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?
|
Brandão, M.
|
|
|
30 |
11 |
p. 1677-1681
|
article
|
| 23 |
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration
|
Mountzios, G.
|
|
|
30 |
11 |
p. 1686-1688
|
article
|
| 24 |
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes
|
Sveen, A.
|
|
|
30 |
11 |
p. 1682-1685
|
article
|
| 25 |
Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach
|
Salama, M.
|
|
|
30 |
11 |
p. 1760-1775
|
article
|
| 26 |
Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice
|
Beer, Philip A.
|
|
|
30 |
11 |
p. 1691-1694
|
article
|
| 27 |
Table of Contents
|
|
|
|
30 |
11 |
p. iii-v
|
article
|
| 28 |
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
|
Tarazona, N.
|
|
|
30 |
11 |
p. 1804-1812
|
article
|
| 29 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
|
Hortobagyi, G.N.
|
|
|
30 |
11 |
p. 1842
|
article
|
| 30 |
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy
|
Boffetta, P.
|
|
|
30 |
11 |
p. 1844
|
article
|
Journal description